RSV shot prevents pneumonia with 80 percent efficacy in older adults, J&J says
By
Alicia Lasek
Oct 05, 2021
A vaccine candidate developed to protect vulnerable adults against the common respiratory syncytial virus has shown 80% efficacy in reducing the risk of dangerous lower respiratory tract diseases such...
No unexpected pattern of adverse booster shot reactions reported by CDC app users
By
Alicia Lasek
Sep 30, 2021
Most v-safe app respondents reported mild to moderate, transient reactions, usually the day after vaccination, CDC investigators say. Sixty percent of respondents were between the ages of 50 and 74.
Clinical briefs for Wednesday, Sept. 22
By
Alicia Lasek
Sep 22, 2021
New data show J&J’s COVID vaccine 94 percent effective with a second dose, company says … Feds partner with AMDA in $10.5M immunization campaign … One in three caregivers say they’ll refuse COVID...
Clinical briefs for Friday, Aug. 27
By
Alicia Lasek
Aug 27, 2021
Big name audio companies fill in while hearing aid reform lags: report … Second J&J shot ‘significantly’ increases COVID-19 antibodies, says firm, which heads toward approval process … AHCA releases...
Second J&J shot ‘significantly’ increases COVID-19 antibodies; firm heads toward approval process
By
Danielle Brown
Aug 26, 2021
A Johnson & Johnson COVID-19 booster could be made available to long-term care residents and healthcare providers, as well as the rest of the American public, after the company unveiled promising results...
CDC safety panel: J&J vaccine benefits outweigh rare neuro risks seen in older adults
By
Alicia Lasek
Jul 26, 2021
The benefits of the shot — including reduced hospitalization, intensive care unit admission and death — outweigh the risk of contracting Guillain-Barre syndrome, the Advisory Committee on Immunization...
Clinical briefs for Thursday, July 15
By
Alicia Lasek
Jul 15, 2021
FDA adds provider warning to J&J vaccine regarding rare neurological disorder … Biogen’s dementia drug Aduhelm could cost Medicaid up to $2.2 billion a year … Biden to nominate West Virginia’s...
What exactly are we waiting to see? It’s time to act on mandates
By
Kimberly Marselas
Jul 14, 2021
As a coalition of long-term care medical and infectious disease experts Tuesday called on healthcare facilities to require COVID-19 vaccines as a condition of employment, I couldn’t help but think of...
Clinical briefs for Tuesday, July 13
By
Alicia Lasek
Jul 13, 2021
FDA to add warning of rare nerve condition to J&J COVID-19 vaccine … Biden combats drug pricing in executive order; imports from Canada a possibility … Neurologists issue ethical guidance for dementia...
J&J vaccine effective against COVID Delta variant, drugmaker says
By
Alicia Lasek
Jul 06, 2021
Johnson & Johnson’s single-shot COVID-19 vaccine prompts a “strong neutralizing antibody response” that lasts at least eight months, the drugmaker has announced.